Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 518 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Rash Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Subantimicrobial Doxycycline in Acne

NCT05399290
View directory record Official record
Conditions
Acne Vulgaris, Pediatrics
Interventions
Doxycycline Hyclate
Drug
Lead sponsor
Michigan State University
Other
Eligibility
13 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815280
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Glendale, Arizona • Rogers, Arkansas • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 31, 2026, 10:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

NCT02037347
View directory record Official record
Conditions
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions
Palifermin
Drug
Lead sponsor
Brett King
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Bridgeport, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Results available

Measuring Adherence in Subjects With Acne Vulgaris in a Clinic Population Subtitle: Topical Benzoyl Peroxide for Acne

NCT00658112
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Benzoyl Peroxide
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 31, 2026, 10:23 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris

NCT07532603
View directory record Official record
Conditions
Lichen Planopilaris
Interventions
Oral Brepocitinib, Placebo
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 31, 2026, 10:23 PM EDT
Not yet recruiting Phase 2 Interventional

Nemolizumab for LS

NCT07704775
View directory record Official record
Conditions
Lichen Sclerosus of Vulva
Interventions
Nemolizumab 30 mg
Biological
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Joovvin' for Your Skin Health Study

NCT04471896
View directory record Official record
Conditions
Skin Inflammation, Acne, Skin Diseases, Dermatological Non-Disease, Skin Condition, Eczema
Interventions
Joovv Mini
Device
Lead sponsor
ProofPilot
Industry
Eligibility
18 Years to 80 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2021 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Topical ASC-J9 Cream for Acne

NCT01289574
View directory record Official record
Conditions
Acne
Interventions
ASC-J9
Drug
Lead sponsor
AndroScience Corp
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 31, 2026, 10:23 PM EDT
Enrolling by invitation Not applicable Interventional

Neonatal Intensive Care Unit (NICU) Diaper Dermatitis: Prevention and Treatment With Airtime

NCT06958003
View directory record Official record
Conditions
Diaper Dermatitis
Interventions
Air Therapy
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
30 Weeks to 1 Year
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Tretinoin Cream 0.025% and RETIN-A® Cream 0.025% in the Treatment of Acne Vulgaris

NCT04724473
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin Cream 0.025%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,030 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne

NCT03450369
View directory record Official record
Conditions
Acne Vulgaris
Interventions
NB01
Biological
Lead sponsor
Naked Biome, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris

NCT02959970
View directory record Official record
Conditions
Acne Vulgaris
Interventions
dapsone gel
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
9 Years to 11 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
20
States / cities
Birmingham, Alabama • Fremont, California • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris

NCT03341910
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%, DFD-03 Vehicle Lotion 0%, Tazorac Vehicle Cream 0%
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 31, 2026, 10:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety and Efficacy of Candela Technology

NCT06202274
View directory record Official record
Conditions
Hair Reduction, Tattoo Removal, Wrinkle, Acne, Scars, Benign Cutaneous Vascular Lesions, Skin Conditions
Interventions
Nordlys, Gentle, Picoway, Vbeam, Profound, Profound Matrix, eTwo, Exceed, CO2RE
Device
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Jacksonville, Florida • Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 31, 2026, 10:23 PM EDT
Withdrawn Not applicable Interventional

Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris

NCT00814918
View directory record Official record
Conditions
Acne Vulgaris
Interventions
5-ALA with Blu-U Light, 5-ALA with Candela V-beam Pulse Dye Laser
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris

NCT03128723
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Acne Mask
Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
12 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 31, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acid Supplementation in Acne Patients

NCT01764308
View directory record Official record
Conditions
Acne
Interventions
Omega-3, Placebo
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

NCT01149876
View directory record Official record
Conditions
Hyperpigmentation
Interventions
Nu Skin Product, Cosmetic instrument, Tretinoin cream 0.05, CeraVe moisturizer
Other · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 31, 2026, 10:23 PM EDT
Not listed Phase 4 Interventional

A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne

NCT01422785
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin phosphate 1.2%/tretinoin 0.025% gel alone, clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Drug
Lead sponsor
Zeichner, Joshua, M.D.
Individual
Eligibility
12 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 31, 2026, 10:23 PM EDT
Terminated Not applicable Interventional Results available

CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants

NCT02299206
View directory record Official record
Conditions
Diaper Rash
Interventions
CeraVe Baby Diaper Rash Cream, Desitin Maximum Strength Original Paste
Drug
Lead sponsor
Northwestern University
Other
Eligibility
3 Months to 18 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles

NCT03312543
View directory record Official record
Conditions
Skin Aging
Interventions
Active Mask, Sham Mask
Device
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 31, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

NCT05966584
View directory record Official record
Conditions
Breast Cancer
Interventions
Benralizumab, fulvestrant or AIs) and PI3K inhibition (alpelisib)
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris

NCT03433378
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin cream, 0.05%, RETIN-A® (tretinoin) cream, 0.05%, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2018 · Synced Oct 31, 2026, 10:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers

NCT01755247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Topical Gel Vehicle, 8% NVN1000 Topical Gel, 8% NVN1000 Topical Gel and moisturizer
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 31, 2026, 10:23 PM EDT